In HER2+ colorectal cancer, anti-HER2 therapy may be less toxic alternative
Patients whose metastatic colorectal cancer has progressed following chemotherapy and who lack mutations in the RAS and BRAF ...
Hosted on MSN11d
Amgen's Lumakras Gets FDA Nod for Expanded Use in Colorectal Cancer
Amgen AMGN announced that the FDA has approved its KRAS inhibitor, Lumakras (sotorasib), in combination with its anti-EGFR ...
Reuters15d
US FDA approves Amgen's colorectal cancer therapy
which occurs in 3% to 5% of colorectal cancers, while Vectibix is a monoclonal antibody that targets a mutated form of the EGFR gene, known for causing rapid tumor cell growth. The approval was ...
ascopubs.org5d
Disparities in prophylactic tetracycline use among patients with metastatic colorectal cancer undergoing treatment with EGFR inhibitors.
Real-world genomic testing performance in colorectal cancer (CRC): The MultiTEAM Systems Framework Precision Oncology Reflex Testing (TEAMSPORT). This is an ASCO Meeting Abstract from the 2025 ASCO ...
Lutris Pharma Secures $30 Million Financing to Advance the Development of Biopharmaceutical to Improve Anti-Cancer Drug Effectiveness
Lutris Pharma, a clinical stage biopharmaceutical company focused on improving anti-cancer therapies by reducing cutaneous ...
ascopubs.org5d
Digesting danger: A two-decade study exploring the association between food processing and colon cancer.
The efficacy of anti-EGFR therapy across different lines of treatment in RAS wild-type left-sided metastatic colorectal cancer. Multi-target stool-DNA test for colorectal cancer screening and effects ...
Cure Today5d
Study Shows Poor Outcomes in BRAF V600E-Mutant Metastatic CRC
BRAF V600E-mutant metastatic colorectal cancer (CRC) was associated with poor clinical outcomes in patients receiving ...
GlobalData on MSN9d
J&J’s Lazcluze/Rybrevant combination obtains European approval to treat NSCLC
The Lazcluze plus Rybrevant combination could challenge AstraZeneca’s standard-of-care Tagrisso in non-small cell lung cancer ...
Targeted Oncology14d
FDA Oks Sotorasib/Panitumumab in KRAS G12C-Mutant Colorectal Cancer
The FDA has approved the combination of sotorasib (Lumakras) and panitumumab (Vectibix) for the treatment of patients with previously treated KRAS G12C-mutated colorectal cancer (CRC). The approval is ...